SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________ |
|
FORM 8-K |
CURRENT REPORT
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
________________ |
| |
Date of Report (Date of earliest event reported):
March 15, 2007
|
Alpharma Inc.
|
| |
(Exact name of registrant as specified in its charter) |
| |
Delaware
(State or other jurisdiction of incorporation) | 1-8593
(Commission File
Number) | 22-2095212
(IRS Employer Identification) |
| |
One Executive Drive, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code) |
| |
Registrant's telephone number, including area code
(201) 947-7774 |
| |
| |
Not Applicable |
______________________________________________
(Former name or former address, if changed since |
last report) |
Item 7.01 Regulation FD Disclosure.
On March 15, 2007, Alpharma Inc. (the "Company") issued a press release announcing that it plans to sell $200 million of Convertible Senior Notes due 2027 in a public offering, pursuant to an effective registration statement filed with the Securities and Exchange Commission. A copy of the press release is attached as Exhibit 99.1.
The information in the preceding paragraph, as well as in Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
ITEM 9.01 | Financial Statements and Exhibits. |
The following Exhibit is filed as a part of this report:
99.1 Company Press Release dated March 15, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ALPHARMA INC.
|
| | By: /s/ Robert F. Wrobel |
| | Name: Robert F. Wrobel
Title: Executive Vice President and CLO |
Date: March 15, 2007
